NxStage Medical Inc. (NASDAQ:NXTM) rose 2.2% on Tuesday . The stock traded as high as $24.54 and last traded at $24.48, with a volume of 150,326 shares. The stock had previously closed at $23.95.

NXTM has been the subject of several research analyst reports. BTIG Research reaffirmed a “buy” rating and issued a $27.00 price objective on shares of NxStage Medical in a report on Tuesday, June 7th. Piper Jaffray Cos. reissued a “buy” rating and issued a $21.00 price target on shares of NxStage Medical in a report on Friday, June 3rd. Zacks Investment Research raised shares of NxStage Medical from a “hold” rating to a “buy” rating and set a $24.00 price target for the company in a report on Wednesday, July 6th. Jefferies Group upped their price target on shares of NxStage Medical from $24.00 to $27.00 and gave the company a “buy” rating in a report on Friday, August 5th. Finally, Canaccord Genuity upped their price target on shares of NxStage Medical from $22.00 to $26.00 and gave the company a “buy” rating in a report on Tuesday, August 2nd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $26.43.

The stock has a 50 day moving average of $23.69 and a 200-day moving average of $19.60. The company’s market cap is $1.56 billion.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/nxstage-medical-inc-nxtm-stock-price-up-2-2.html

NxStage Medical (NASDAQ:NXTM) last released its quarterly earnings data on Thursday, August 4th. The medical device company reported ($0.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.04) by $0.01. NxStage Medical had a negative return on equity of 3.79% and a negative net margin of 2.06%. The firm earned $92.20 million during the quarter, compared to analyst estimates of $89.44 million. During the same period in the prior year, the company posted ($0.08) earnings per share. The business’s revenue for the quarter was up 14.8% compared to the same quarter last year. Analysts expect that NxStage Medical Inc. will post ($0.12) earnings per share for the current year.

In other NxStage Medical news, Director Craig W. Moore sold 3,000 shares of the stock in a transaction on Wednesday, September 14th. The stock was sold at an average price of $23.31, for a total transaction of $69,930.00. Following the completion of the transaction, the director now directly owns 90,739 shares in the company, valued at $2,115,126.09. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 4.70% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Outfitter Advisors LTD. raised its position in NxStage Medical by 7.6% in the first quarter. Outfitter Advisors LTD. now owns 58,400 shares of the medical device company’s stock valued at $875,000 after buying an additional 4,100 shares in the last quarter. Prudential Financial Inc. raised its stake in shares of NxStage Medical by 32.4% in the first quarter. Prudential Financial Inc. now owns 324,586 shares of the medical device company’s stock worth $4,866,000 after buying an additional 79,500 shares during the period. Algert Global LLC raised its stake in shares of NxStage Medical by 82.1% in the first quarter. Algert Global LLC now owns 33,346 shares of the medical device company’s stock worth $500,000 after buying an additional 15,032 shares during the period. BlackRock Group LTD raised its stake in shares of NxStage Medical by 11.7% in the first quarter. BlackRock Group LTD now owns 68,747 shares of the medical device company’s stock worth $1,030,000 after buying an additional 7,176 shares during the period. Finally, Menta Capital LLC acquired a new stake in shares of NxStage Medical during the first quarter worth $552,000. Hedge funds and other institutional investors own 98.26% of the company’s stock.

NxStage Medical Company Profile

NxStage Medical, Inc is a medical device company. The Company is engaged in the development, manufacturing and marketing of products for the treatment of kidney failure, fluid overload and related blood treatments and procedures. The Company’s products include the System One, Streamline Blood Tubing Sets and AV Fistula and Apheresis Needles.

5 Day Chart for NASDAQ:NXTM

Receive News & Ratings for NxStage Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.